RLT

The Role of PSMA-Targeted Antibodies in Prostate Cancer

Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.

Latest News

PSMA RLT for Oligometastatic Prostate Cancer

Amar Kishan, MDRLT | April 3, 2025

Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.

FDA Approves 177Lu Vipivotide Tetraxetan for PSMA+ mCRPC Treatment Before Chemotherapy

Emily MenendezCRPC | March 31, 2025

177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.

Evaluating Safety and Efficacy of PSMA Therapy in the Castration-Sensitive Setting

Michael Morris, MDmHSPC | March 31, 2025

Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.

Improving Prostate Cancer Outcomes With Combination Therapy

Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICDRLT | March 31, 2025

Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.

PSMA and Beyond 2025: Reviewing the Agenda

Jérémie Calais, MD, PhDRLT | March 26, 2025

Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.

ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC

Emily MenendezRLT | March 7, 2025

Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.

Expert Interviews

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer

Localized

nmCRPC

CRPC

mHSPC

Prostate Cancer Diagnostics

Prostate Cancer

Localized

nmCRPC

CRPC

Conference Coverage

Dr. David Canes on WellPrept - Boosting Patient Education and Improving Care

David Canes, MDUrothelial Carcinoma | May 7, 2025

Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.

Guidelines for Measuring Patient Outcomes and Quality Improvements in GU Oncology

Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025

Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.

ctDNA in GU Oncology: History, Current Studies, and Benefits

John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025

John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.

cT1a and cT1b-cT2 RCC: Who is at Risk of Upstaging to pT3a?

Victor Sandoval, MD, MScLocalized Renal Cell Carcinoma | May 5, 2025

Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.

Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection

Simpa Salami, MD, MPHProstate Cancer Diagnostics | May 5, 2025

Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.

Exploring Survival Outcomes of nccRCC With Tumor Thrombus Extension

Joseph Cheaib, MDnccRCC | May 5, 2025

Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.

Roundtables

A Look at Lutetium-177-PSMA & Analyzing the VISION Study

GU Oncology Now EditorsRoundtable | February 28, 2023

The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.

Additional PSMA Therapies Being Studied

GU Oncology Now EditorsRoundtable | February 28, 2023

Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.